Helixmith Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Viromed Co., Ltd. (to 2019)
3
Ending by 2030
Aug 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 5 to 7, 2027 · next Nov 5
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,812,146 | Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor In force · From the USPTO record | In force | From the USPTO record | |
| US 8,389,492 | Lyophilized DNA formulations for enhanced expression of plasmid DNA In force · From the USPTO record | In force | From the USPTO record | |
| US 8,168,859 | Ubiquitin regulatory elements In force · From the USPTO record | In force | From the USPTO record | |
| US 9,963,493 | Gene Therapy for Diabetic Neuropathy Using an HGF Isoform In force · High confidence | In force | High confidence | |
| US 10,759,841 | Gene Therapy for Diabetic Neuropathy Using an HGF Isoform In force · High confidence | In force | High confidence | |
| US 10,639,351 | Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor In force · From the USPTO record | In force | From the USPTO record | |
| US 10,927,177 | Methods of treatment using anti-c-met antibodies In force · From the USPTO record | In force | From the USPTO record | |
| US 11,279,769 | Anti-Sialyl TN Chimeric Antigen Receptors In force · High confidence | In force | High confidence | |
| US 11,541,097 | Crude Drug Composition For Preventing Or Treating Respiratory Diseases In force · High confidence | In force | High confidence | |
| US 11,559,555 | Crude Drug Composition for Preventing or Treating Respiratory Diseases In force · High confidence | In force | High confidence |
Also on record, not counted in the 16: 1 lapsed for an unpaid fee · 4 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 abandoned · 11 no status recorded